Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 17/20 | 1.00 |
| ▸ | GSK3A | P49840 | 15/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.51 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.51 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6428260 | 0.89 | GSK3B (0.80) | GSK3BGSK3ACCNB2CDK1CCNB1 | |
| SCHEMBL6427365 | 0.85 | GSK3A (0.73) | GSK3BGSK3ACCNB2CDK1CCNB1 | |
| SCHEMBL3382637 | 0.82 | GSK3A (1.00) | GSK3BGSK3AGAA | |
| SCHEMBL6427982 | 0.82 | GSK3A (0.69) | GSK3BGSK3ACCNB2CDK1CCNB1 | |
| SCHEMBL3383077 | 0.81 | GSK3A (1.00) | GSK3BGSK3ACCNB2CDK1CCNB1 | |
| SCHEMBL3384854 | 0.81 | GSK3A (1.00) | GSK3BGSK3ACCNB2CDK1CCNB1 | |
| SCHEMBL3382636 | 0.81 | GSK3A (1.00) | GSK3BGSK3ACCNB2CDK1CCNB1 | |
| SCHEMBL3384147 | 0.78 | GSK3A (1.00) | GSK3BGSK3A | |
| SCHEMBL6015126 | 0.76 | GSK3B (1.00) | GSK3BGSK3APGR | |
| SCHEMBL15354264 | 0.72 | GSK3B (1.00) | GSK3BGSK3APGRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569346-B1 | Thiazoline ring compounds as botulinum antagonists | BIOMADISON, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| WO-2012065065-A9 | METHODS AND COMPOSITIONS FOR MODULATING HAIR GROWTH, WOUND HEALING AND SCAR REVISION | FOLLICA, INC. (US) | 2012-10-11 | — | — | WO | disclosed |
| WO-2012065065-A1 | METHODS AND COMPOSITIONS FOR MODULATING HAIR GROWTH, WOUND HEALING AND SCAR REVISION | FOLLICA, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| US-7781463-B2 | Enzyme inhibitors | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2010-08-24 | — | — | US | disclosed |
| US-7666885-B2 | Neurodegenerative disease; anticancer agents; hyperplasia; arterosclerosis; restenosis; non-insulin dependent diabetis; Alzheimer's disease | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2010-02-23 | — | — | US | disclosed |
| US-20080033012-A1 | Enzyme inhibitors | COSENJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS, A SPAIN CORPORATION | 2008-02-07 | — | — | US | disclosed |
| US-6872737-B2 | Heterocyclic inhibitors of glycogen synthase kinase GSK-3 | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2005-03-29 | — | — | US | disclosed |
| US-20050014803-A1 | Enzyme inhibitors | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS, A SPAIN CORPORATION | 2005-01-20 | — | — | US | disclosed |
| US-20030195238-A1 | Drugs such as 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5 -dione inhibitors of glycogen synthase kinase-3 (GSK-3), for prophylaxis of neurodegenerative disorders, cancer, hyperplasia, psoriasis, arteriosclerosis or restinosis | UNIVERSIDAD AUTONOMA DE MADRID (UAM) (ES) | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033012-A1 | Enzyme inhibitors | GSK3B, GSK3A, IDE | GSK3B 1/4885GSK3A 2/4885CCNB2 397/4885 |
| US-20030195238-A1 | Drugs such as 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5 -dione inhibitors of glycogen synthase kinase-3 (GSK-3), for prophylaxis of neurodegenerative disorders, cancer, hyperplasia, psoriasis, arteriosclerosis or restinosis | GSK3B, GSK3A, GSKIP | GSK3B 1/4885GSK3A 2/4885CCNB2 516/4885 |
| US-20050014803-A1 | Enzyme inhibitors | GSK3B, GSK3A, IDE | GSK3B 1/4885GSK3A 2/4885CCNB2 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.